Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups , but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks ( mean mTSS at week 52 = 2.56 vs 3.30 , P < 0.001 ) .